News Search Results
Sep 05, 2024, 10:00 ET Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
partnerships with local academic institutions and biotech innovators, underpinning our commitment to pursue transformative treatments in oncology, ophthalmology and rare diseases for patients in need." Fostering External Research Collaborations to Nurture Innovation and Drug DiscoveryThe
More news about: ASTELLAS PHARMA INC.
Sep 04, 2024, 08:46 ET Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnologies
Sep 04, 2024, 08:37 ET Myoptechs Announces $2.0 Million Fundraise and Provides Update on Clinical Development Program
Health Organization; 2015.2 Haarman, A.E.G., et al., The Complications of Myopia: A Review and Meta-Analysis. Investigative Ophthalmology & Visual Science April 2020, Vol.61, 49.
More news about: Myoptechs
Sep 04, 2024, 08:30 ET InMode to Present at 2024 Baird Global Healthcare Conference
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Sep 04, 2024, 08:00 ET Lindus Health Launches "All-in-One Ophthalmology CRO" Tailored to Clinical Trials in Ophthalmology
execute ophthalmology trials," said Michael Young, co-founder at Lindus Health. "We're incredibly excited to debut our one-of-a-kind CRO and technology offering within this market segment." The "All-in-One Ophthalmology CRO" offering provides ophthalmology sponsors
More news about: Lindus Health
Sep 04, 2024, 08:00 ET Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA's clinical trials network
companies throughout the world. The company has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, and neuroscience. Today, we are part of the Emmes Group, helping transform the future of clinical research. Learn more at
More news about: Emmes
Sep 04, 2024, 08:00 ET SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics
pharmaceutical companies on the development of their pipeline candidates in therapeutic areas of immunology, dermatology, oncology, cardiology, ophthalmology, and central nervous system indications. Dr. Gubbi has headed 9 successful submissions to regulatory agencies such as the U.S. Food and Drug Administration,
More news about: SFA Therapeutics, Inc.
Sep 04, 2024, 07:45 ET Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies
programs, the Company has validating CNS partnerships with AbbVie, Lilly, CRISPR Therapeutics, and the AbbVie partnership was expanded to include ophthalmology disorders. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research
More news about: Capsida Biotherapeutics
Sep 04, 2024, 06:00 ET Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
company's product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand. EVA Pharma is one of the
More news about: Eli Lilly and Company
Sep 03, 2024, 20:00 ET Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its PD-1/IL-2α Bispecific
More news about: Innovent Biologics
Sep 03, 2024, 17:40 ET Orthokeratology Lens Market to Grow by USD 248 Million (2024-2028) as Global Myopia Rates Rise, Report Highlights AI's Role in Market Transformation - Technavio
and are increasingly popular due to their non-surgical nature and convenience. Healthcare providers, including optometrist clinics, hospitals, ophthalmology clinics, and optometry clinics, offer orthokeratology lenses as an alternative to elective surgical procedures like LASIK surgeries, Photorefractive
More news about: Technavio
Sep 03, 2024, 13:19 ET ViaLase präsentiert auf dem 42. Kongress der European Society of Cataract and Refractive Surgeons (ESCRS)
Ophthalmology Futures European Forum teilnehmen, das am 5. September in Barcelona stattfindet. „Nachdem wir die CE-Zulassung
More news about: ViaLase, Inc.
Sep 03, 2024, 09:03 ET ViaLase presente en el 42º Congreso de la European Society of Cataract and Refractive Surgeons (ESCRS)
Ophthalmology Futures European Forum, que se celebrará en Barcelona el 5 de septiembre. "Tras recibir la aprobación
More news about: ViaLase, Inc.
Sep 03, 2024, 09:00 ET Somite Therapeutics Announces Round Extension with Astellas Venture Management and Montage Ventures Joining as Board Observers
Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas, "AIRM") focus on regenerative medicine and cell therapy research in ophthalmology and other therapeutic areas that have few or no available treatment options, while Montage Ventures has built a robust thesis and has deep insights
More news about: Somite Therapeutics
Sep 03, 2024, 08:00 ET ViaLase to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS)
Ophthalmology Futures European Forum, which takes place on September 5th in Barcelona.
More news about: ViaLase, Inc.
Sep 03, 2024, 08:00 ET ViaLase to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS)
Ophthalmology Futures European Forum, which takes place on September 5th in Barcelona.
More news about: ViaLase, Inc.
Sep 03, 2024, 03:45 ET THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Sep 01, 2024, 20:13 ET Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that multiple clinical study results of mazdutide (GLP-1R/GCGR dual agonist) will be presented at the European
More news about: Innovent Biologics
Aug 29, 2024, 08:00 ET ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
Europe's leading refractive and cataract surgeons," says Euan S. Thomson, Ph.D., President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at ZEISS Medical Technology. "Using our latest offerings – including our VISUMAX 800
More news about: Carl Zeiss Meditec AG
Aug 29, 2024, 08:00 ET ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
Europe's leading refractive and cataract surgeons," says Euan S. Thomson, Ph.D., President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at ZEISS Medical Technology. "Using our latest offerings – including our VISUMAX 800
More news about: Carl Zeiss Meditec AG
Aug 29, 2024, 01:27 ET Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics Ltd.
Aug 29, 2024, 01:13 ET Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics Ltd.
Aug 28, 2024, 20:00 ET Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that nearly 20 accepted clinical data of its novel oncology molecules, including six oral presentations, will
More news about: Innovent Biologics
Aug 28, 2024, 09:00 ET JEDMED Joins MellingMedical's Lineup of Medical Products Providers
that providing unsurpassed customer support before, during, and after the sale is ultimately the key to their success, JEDMED specializes in ENT, ophthalmology, dental, telemedicine, audiology, and speech pathology solutions. To learn more, visit
More news about: MellingMedical
Aug 28, 2024, 06:37 ET Innovent Announces 2024 Interim Results and Business Updates
company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2024 interim results and major business updates. Dr. Michael Yu,
More news about: Innovent Biologics